Precision Promise Platform Trial for Metastatic Pancreatic Cancer Precision PromiseSM

Brief description of study

The purpose of this study is to hope that Precision PromiseSM will change the landscape of clinical development in pancreatic cancer and open the door to longer and better lives for all patients with this disease. This platform trial is designed to increase access to therapeutic trials across the pancreatic cancer community and will allow more rapid completion of testing and approval of new therapies. Additionally, the study design reduces clinical trial start-up and execution times and has the potential for rapidly testing multiple combination therapies simultaneously. Lastly, Precision PromiseSM enhances the patient experience as it reduces the number of patients being randomized to standard of care therapies.

Clinical Study Identifier: s19-01345 Identifier: NCT04229004
Principal Investigator: Diane Simeone.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.